Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Non-Current Assets of $1.7 billion for Q1 2026, down 6.06% year-over-year from $1.9 billion in Q1 2025, and down 1.4% quarter-over-quarter from $1.8 billion in Q4 2025.
Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $1.7 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 6.06% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.1 billion (down 8.16% YoY), while the FY2025 annual figure was $1.8 billion, down 7.66% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.7 billion, down from $1.8 billion in the prior quarter.
- The five-year high for Non-Current Assets was $2.5 billion in Q1 2022, with the low at $1.7 billion in Q1 2026.
- The 5-year median for Non-Current Assets is $2.1 billion (2024), against an average of $2.1 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets rose 4.12% in 2022, then dropped 12.7% in 2024.
- Amneal Pharmaceuticals' Non-Current Assets stood at $2.4 billion in 2022, then decreased by 12.26% to $2.1 billion in 2023, then dropped by 8.64% to $1.9 billion in 2024, then retreated by 7.66% to $1.8 billion in 2025, then fell by 1.4% to $1.7 billion in 2026.
- Business Quant data shows AMRX's Non-Current Assets at $1.7 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 1.83 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Bn |
| Mar 31, 2026 | 1.74 Bn |
| Dec 31, 2025 | 1.77 Bn |
| Sep 30, 2025 | 1.76 Bn |
| Jun 30, 2025 | 1.84 Bn |
| Mar 31, 2025 | 1.85 Bn |
| Dec 31, 2024 | 1.91 Bn |
| Sep 30, 2024 | 1.95 Bn |
| Jun 30, 2024 | 2.02 Bn |
| Mar 31, 2024 | 2.08 Bn |
| Dec 31, 2023 | 2.09 Bn |
| Sep 30, 2023 | 2.23 Bn |
| Jun 30, 2023 | 2.28 Bn |
| Mar 31, 2023 | 2.32 Bn |
| Dec 31, 2022 | 2.39 Bn |
| Sep 30, 2022 | 2.45 Bn |
| Jun 30, 2022 | 2.49 Bn |
| Mar 31, 2022 | 2.50 Bn |
| Dec 31, 2021 | 2.42 Bn |
| Sep 30, 2021 | 2.40 Bn |